Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

Academic Article

Abstract

  • We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities. Copyright © 2013 by Lippincott Williams & Wilkins.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Yanik EL; Napravnik S; Ryscavage P; Eron JJ; Koletar SL; Moore RD; Zinski A; Cole SR; Hunt P; Crane HM
  • Start Page

  • 216
  • End Page

  • 220
  • Volume

  • 63
  • Issue

  • 2